COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel or Doxorubicin in Locally Advanced Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00123929
Recruitment Status : Completed
First Posted : July 26, 2005
Last Update Posted : August 6, 2009
UNC Lineberger Comprehensive Cancer Center
Information provided by:
Hospital San Carlos, Madrid

Brief Summary:
After a core biopsy of the tumor is obtained, patients with locally advanced breast cancer are randomized to receive 4 cycles of full dose doxorubicin (75 mg/m2 e3w) or docetaxel (100 mg/m2 e3w). After the fourth cycle, patients are submitted to surgery to ascertain pathological response. They then receive the opposite drug, hormones, Herceptin, and radiation as indicated.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: docetaxel Drug: doxorubicin Phase 2

Detailed Description:
The aim of the study is to define the genetic signature which predicts the response to single drug doxorubicin versus docetaxel. 250 patients will be included. cDNA microarrays will be produced and the genetic pattern will be correlated with the response to doxorubicin and docetaxel. Secondary aim is the prediction of response by means of IHC determinations (her2, ER, PgR, Ki67, protein TAU), FISH (topoisomerase II alpha, her2) and PCR (topoisomerase II alpha).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 250 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Patterns of Genetic Expression Associated to Sensibility to Doxorubicin Versus Docetaxel as Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer
Study Start Date : January 2005
Actual Primary Completion Date : May 2009
Actual Study Completion Date : May 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Active Comparator: 1
Drug: doxorubicin
75 mg/m2 every 3 weeks times 4
Other Name: adriamycin

Drug: docetaxel
100 mg/m2 every 3 weeks times 4
Other Name: taxotere

Primary Outcome Measures :
  1. correlation of genetic tumoral pattern with response to docetaxel versus doxorubicin [ Time Frame: 2005-2009 ]

Secondary Outcome Measures :
  1. response rate to doxorubicin versus docetaxel [ Time Frame: 2005-2013 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Locally advanced, inoperable breast carcinoma or stage II not amenable to breast preserving surgery (amendment introduced on november 2006)
  • Signed informed consent

Exclusion Criteria:

  • Age >75
  • Cardiac disease; LEFT <50%
  • Hyperbilirubinemia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00123929

Layout table for location information
Servicio de Oncologia Medica, Hospital Clinico San Carlos
Madrid, Spain, 28040
Sponsors and Collaborators
Hospital San Carlos, Madrid
UNC Lineberger Comprehensive Cancer Center
Layout table for investigator information
Study Director: Eduardo Diaz-Rubio, MD, PhD Servicio de Oncologia Medica, Hospital Universitario San Carlos, Madrid, Spain
Principal Investigator: Martin Miguel, MD, PhD Hospital San Carlos, Madrid, Spain
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Miguel Martin, MD, Hospital San Carlos Identifier: NCT00123929    
Other Study ID Numbers: 05/117
First Posted: July 26, 2005    Key Record Dates
Last Update Posted: August 6, 2009
Last Verified: August 2009
Keywords provided by Hospital San Carlos, Madrid:
breast cancer
neoadjuvant chemotherapy
genetic signature
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors